WebAug 5, 2024 · Trial Phase 2, GLOW. Fixed-duration ibrutinib + venetoclax showed superior efficacy in older or unfit patients with chronic lymphocytic leukaemia (CLL) compared with chlorambucil + obinutuzumab in the phase 3 GLOW study. These results support the positive clinical profile of all-oral, once-daily, fixed-duration ibrutinib + venetoclax as first ... WebDec 15, 2024 · The Phase 3 GLOW trial (n=507) is a global, multi-center, double-blind, randomized study assessing the efficacy and safety of zolbetuximab plus CAPOX compared to placebo plus CAPOX.
Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 GLOW …
WebApr 20, 2024 · Participants will receive a loading dose of zolbetuximab at Cycle 1 Day 1 followed by a lower dose in subsequent cycles every 3 weeks. Additionally, participants will receive up to 12 treatments of mFOLFOX6 (or components of mFOLFOX6 if some components are discontinued due to toxicity) over 4 or more cycles (each cycle is … WebJun 12, 2024 · The GLOW study is a randomized, open label Phase 3 trial comparing progression-free survival in patients treated with either I+V or C+O as assessed by an Independent Review Committee. matt welch reason
News Astellas Pharma Inc.
WebAug 9, 2024 · GLOW season 3 is a final hurrah to the ladies of wrestling. Don't underestimate this show if you like off-the-wall misanthropic dramatic series. It's a shame … WebDec 10, 2024 · The GLOW study (NCT03462719) is a randomized, open-label, Phase 3 trial that evaluated the efficacy and safety of first-line, fixed-duration I+V versus Clb+O in elderly patients (≥65 years of age) with CLL/SLL, or patients ages 18-64 with a cumulative illness rating scale (CIRS) score of greater than six or creatinine clearance less than 70 ... While follow-up in the GLOW trial is limited and study populations differ, particularly with respect to inclusion of patients with del(17p), there are now multiple phase 3 trials evaluating non-chemoimmunotherapy treatments (single-agent ibrutinib [NCT01722487], ibrutinib-rituximab [NCT01886872], venetoclax-obinutuzumab [NCT02242942], and ... matt weldon sweatpants